A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

Inclusion Criteria: * Confirmed diagnosis of psoriasis, with significant involvement of genital regions, i.e., sPGA-G greater than or equal to (\>=) 3. * Need for systemic biologic therapy based on the local country specific regulations. Tildrakizumab, in accordance with the SmPC, must be the anti-IL23p19 selected therapy before including the patient in the study. * Age 18 - 99 years. * Informed consent in writing in accordance with applicable country regulations * Patient must have plaque psoriasis affecting a body surface area (BSA) \>= 1% in a non-genital area at baseline. * Patient willing and able to fill out study questionnaires. Exclusion Criteria: * Patient appears to be unwilling or unable to comply with the requirements of the study or who, in the opinion of the investigator, should not participate in the study. * Patient exposed to any experimental treatment in the past 3 months prior to baseline. * Any condition preventing prescription of Tildrakizumab according to the SmPC, including but not restricted to any contraindication or history of hypersensitivity or intolerance. * Patient dependent on the investigator, including but not restricted to employees of the study site. * Previous treatment with Tildrakizumab.